# Fuzzy-to-Fact Quality Review: Synthetic Lethality in Lung Cancer Report

**Report**: `/home/donbr/ai2026/lifesciences-deepagents/output/cqs/synthetic-lethality-lung-cancer-state-of-art.md`

**Competency Question**: "What existing literature, patents, and clinical trials define the current state of art for synthetic lethality approaches in lung cancer?"

**Verdict: PARTIAL**

The report demonstrates strong clinical trial coverage, reasonable CURIE resolution for core entities, and a well-structured evidence grading framework. However, it fails on several critical dimensions: incomplete CURIE resolution for 12 of 16 drugs, zero NCT ID verification (Phase 5 skipped entirely), no patent coverage despite the competency question explicitly requesting it, missing LOCATE-RETRIEVE audit trail for the disease CURIE, and no protein-protein interaction data from STRING/BioGRID (Phase 3 was skipped). These gaps are honestly acknowledged in the Gaps and Limitations section, which is commendable, but they remain protocol failures.

**Score: 5/10 dimensions PASS, 1 N/A, 4 FAIL**

---

## 1. CURIE Resolution -- FAIL

**Details**: The report resolves 13 entities to canonical CURIEs in the Resolved Entities table:
- 5 genes: KRAS (HGNC:6407), TP53 (HGNC:11998), EGFR (HGNC:3236), STK11 (HGNC:11389), PARP1 (HGNC:270)
- 3 gene/targets: ATR (HGNC:882), WEE1 (HGNC:12761), CHEK1 (HGNC:1925)
- 1 disease: NSCLC (EFO_0003060)
- 4 compounds: Olaparib (CHEMBL:521686), Ceralasertib (CHEMBL:4285417), Adavosertib (CHEMBL:1976040), MRTX1719 (PubChem:CID156151242)

**Unresolved entities** (12 drugs explicitly noted as "ChEMBL search not performed"):
- Niraparib, Talazoparib, Rucaparib, Veliparib, AZD5305, Berzosertib, Elimusertib, M1774, Debio 0123, IDE397, S095035, AMG 193

These 12 drugs appear in the Drug Candidates table (lines 112-123) without CURIEs. The report honestly acknowledges this with "(ChEMBL search not performed)" but per the protocol, ALL entities in a Drug Candidates table must have CURIEs. Additionally, the drug target CURIEs in the Drug Candidates table use ChEMBL target IDs (e.g., "CHEMBL:3105" for PARP1, "CHEMBL:5024" for ATR) that do not appear in the Resolved Entities table and are not sourced to any tool call.

**Missing entities that should have been resolved**:
- MAT2A (mentioned as drug target but no HGNC CURIE)
- CDKN2A (mentioned re: 9p21 co-deletion but no HGNC CURIE)
- MTAP (mentioned extensively but no HGNC CURIE)
- SCLC (small cell lung cancer -- no separate disease CURIE despite being discussed as a distinct entity)
- BRCA1/BRCA2 (mentioned in context of PARP inhibitor sensitivity but not resolved)

**CURIE format issue**: The disease CURIE "EFO_0003060" uses an underscore instead of the standard colon format "EFO:0003060" specified in the graph-builder skill (line 117 of SKILL.md: `"EFO:0000574"` or `"MONDO:0018875"`).

---

## 2. Source Attribution -- PASS (with caveats)

**Details**: The report makes a strong effort at source attribution. Every row in the Resolved Entities, Drug Candidates, Clinical Trials, and Evidence Assessment tables includes a `[Source: tool(param)]` citation. The mechanism chain tables in Sections "Mechanism 1-3" also include per-step source citations.

**Sourced claims count**: Approximately 55-60 distinct factual claims with source citations.

**Unsourced claims** (minor):
- Line 6: "four major mechanistic strategies" -- this is a synthesis claim, acceptable without direct sourcing.
- Line 12: "50+ clinical trials" -- a count aggregation, sourced indirectly through the trial tables.
- Line 42: "KRAS mutations (30-40% of lung adenocarcinomas)" -- the prevalence figure is not attributed to a specific tool call, only the association score is sourced.
- Line 58: "TP53 mutations (50-70% of NSCLC, 90%+ of SCLC)" -- partially sourced (Evidence Assessment table notes this is from a single database, Open Targets target description), but the specific percentage is not directly attributed.
- Line 88: "MTAP ... is co-deleted with CDKN2A in ~15% of NSCLC due to chromosomal proximity (9p21)" -- sourced to trial eligibility criteria inference, which the report honestly flags as an L2 claim.

The report correctly uses the `[Source: tool(param)]` format specified in the reporting skill (line 382-389 of reporting SKILL.md).

---

## 3. LOCATE then RETRIEVE Discipline -- PASS (for resolved entities)

**Details**: The Resolved Entities table shows clear evidence of the two-step pattern for the 13 resolved entities:
- Genes show both search and get: e.g., `hgnc_search_genes("KRAS"), hgnc_get_gene("HGNC:6407")` (LOCATE then RETRIEVE).
- Gene/targets show three-step: HGNC search, HGNC get, then Open Targets get: e.g., `hgnc_search_genes("ATR"), hgnc_get_gene("HGNC:882"), opentargets_get_target("ENSG00000175054")`.
- Compounds show search: `chembl_search_compounds("olaparib")` (LOCATE only -- no RETRIEVE via `chembl_get_compound` for any compound, which may reflect the known ChEMBL 500 error avoidance pattern).

**Violations**:
- The 12 unresolved drugs were never LOCATEd at all -- they appear in the report solely from `clinicaltrials_search_trials` results. This is a partial violation: the drug names came from a tool call (trial search), but they were never independently LOCATEd in a compound database.
- The ChEMBL target IDs (CHEMBL:3105, CHEMBL:5024, CHEMBL:5491) in the Drug Candidates table have no LOCATE provenance. These appear to be either from training knowledge or from unstated tool calls.

---

## 4. Disease CURIE in ENRICH Phase -- FAIL

**Details**: The Resolved Entities table lists "Non-small cell lung carcinoma" with CURIE "EFO_0003060" sourced to `opentargets_get_associations("ENSG00000133703")`. This is the KRAS Ensembl ID, suggesting the disease CURIE was extracted as a byproduct of querying KRAS disease associations, not via a dedicated disease resolution step.

**Issues**:
1. The disease CURIE was obtained incidentally from Phase 3-like activity (EXPAND, via `opentargets_get_associations`) rather than deliberately in Phase 1 (ANCHOR) or Phase 2 (ENRICH) as required by the skill.
2. The graph-builder skill (lines 217-224) explicitly states: "LOCATE disease CURIE (use Ensembl ID from HGNC cross-references above)" should happen in Phase 2 ENRICH, not as a side-effect of other queries.
3. SCLC (small cell lung cancer) is discussed throughout (WEE1 trials, PARP trials) but never resolved to a disease CURIE.
4. The broader concept "lung cancer" (which encompasses both NSCLC and SCLC) was never resolved to a parent CURIE (e.g., MONDO:0008903 or EFO:0001071).
5. CURIE format uses underscore (`EFO_0003060`) instead of colon (`EFO:0003060`).

---

## 5. Open Targets Pagination -- PASS (by absence)

**Details**: The report does not appear to have used Open Targets `knownDrugs` GraphQL queries. The Open Targets tools cited are `opentargets_get_target` and `opentargets_get_associations`, which are MCP tool calls rather than direct GraphQL. There is no mention of pagination failures or use of the `size`-only pattern.

Given that the report used MCP tool wrappers rather than direct GraphQL for Open Targets, pagination was handled by the MCP server, making this dimension effectively N/A for protocol compliance. However, the fact that `opentargets_get_target` was used for target profiles but NOT for `knownDrugs` drug discovery is itself a gap -- Open Targets is supposed to be the PRIMARY source for drug discovery (Phase 4a), but the report relied primarily on `clinicaltrials_search_trials` for drug discovery.

Granting a conditional PASS since no pagination errors were encountered.

---

## 6. Evidence Grading -- PASS

**Details**: The report implements the evidence grading system from the reporting skill correctly:

- **Claim-level grades**: 9 claims individually graded in the Evidence Assessment table (lines 186-196), each with a numeric score, level designation (L2-L4), justification, and source citations.
- **Modifiers applied correctly**: Active trial (+0.10), single source (-0.10), mechanism specificity (+0.05) are all applied with explicit justification.
- **Overall confidence**: Median claim score of 0.78 (L3 Functional), range 0.65-0.95 (line 200-201). This follows the "median, not mean" rule from the reporting skill (line 355).
- **Per-mechanism grades**: Each mechanism section includes an evidence level (0.85, 0.80, 0.85, 0.75).
- **Per-drug grades**: The Drug Candidates table includes evidence levels for all 16 drugs.
- **Grading Notes section**: Lines 125-128 explain the grading logic for top candidates.
- **Interpretation narrative**: Lines 203 explains what the overall score means and identifies the weakest claims.

**Minor issues**:
- Some evidence level scores appear generous. The "TP53 mutations in 50-70% of NSCLC" claim at 0.65 (L2) sourced to a single database description could arguably be L1 (single-DB, 0.30-0.49) with a +0.10 modifier for being a target description from a curated database.
- The MTAP co-deletion claim at 0.70 (L3) is sourced to trial eligibility criteria inference, which is creative but may overstate the evidence level (trial criteria are not the same as multi-database concordance).

These are judgment calls within the grading framework, not clear violations.

---

## 7. Gain-of-Function Filter -- N/A

**Details**: Synthetic lethality approaches in lung cancer primarily exploit loss-of-function mutations (TP53 loss, MTAP deletion, BRCA deficiency) or oncogene addiction (KRAS gain-of-function). However, the therapeutic strategy here is to exploit vulnerabilities created by these mutations (e.g., inhibiting backup repair pathways), NOT to directly target the gain-of-function protein with an agonist/antagonist.

The gain-of-function filter (which prevents returning agonists for gain-of-function diseases like FOP) is not directly applicable here because:
1. The drugs identified are inhibitors of compensatory pathways (PARP, ATR, WEE1, MAT2A), not modulators of the mutated oncogene itself.
2. The KRAS G12C inhibitor adagrasib (NCT06130254) is correctly listed as a combination partner, not as the synthetic lethality agent.

This dimension does not apply to this competency question.

---

## 8. Clinical Trial Validation -- FAIL

**Details**: The report lists 26 distinct NCT IDs across four trial categories (PARP: 8, ATR: 7, WEE1: 4, MTAP: 5, plus 2 referenced in mechanism sections). **Every single one is marked "Unverified"**.

The report explicitly acknowledges this on line 178: "Phase 5 validation step (individual NCT ID retrieval via `clinicaltrials_get_trial`) was not performed." And in the Gaps section (line 213): "NCT ID verification not performed."

Per the graph-builder skill Phase 5 (lines 375-401), every NCT ID should be verified via `clinicaltrials_get_trial`. The reporting skill's "Unverified NCT IDs" pitfall section (lines 434-437) explicitly addresses this: marking as "Unverified" is correct behavior when Phase 5 was not run, but **the Phase should have been run**.

Additionally, the report footer (line 268) states: "Protocol: Fuzzy-to-Fact Phases 1-5 (abbreviated -- Phase 3 network expansion and Phase 5 trial verification not fully executed)." This honest acknowledgment is appropriate but does not excuse the failure.

---

## 9. Completeness -- FAIL

**Details**: The competency question asks about three things: **literature**, **patents**, and **clinical trials** for synthetic lethality in lung cancer.

| Dimension | Coverage | Assessment |
|-----------|----------|------------|
| Clinical trials | 26 NCT IDs across 4 mechanism categories, 50+ total identified | STRONG |
| Literature | Indirect only -- protein function descriptions from UniProt/Open Targets; no PubMed searches | WEAK |
| Patents | None -- explicitly acknowledged as a gap | MISSING |

**Clinical trials**: Well covered. The report identifies trials across all four major synthetic lethality strategies (PARP, ATR/CHEK1/WEE1, MTAP/MAT2A, and KRAS combinations). Phase distribution, recruitment status, and combination strategies are documented.

**Literature**: The report does not cite any PubMed searches. The `query_pubmed` tool (or `pubmed_search_articles` via MCP) was apparently never called. Literature evidence comes indirectly through protein function text extracted from Open Targets target descriptions. This is inadequate for a "state of the art" assessment, which typically requires review articles, systematic reviews, or key primary research papers.

**Patents**: The report honestly flags this gap (line 219): "Patent searches were not performed. No MCP tools exist for patent databases (USPTO, EPO, WIPO)." This is factually correct -- there is no patent MCP tool available. However, the report could have noted specific patent families or used the `think_tool` to reason about whether any known patent databases could be queried via `query_api_direct`. The competency question explicitly asks about patents, so this is a coverage failure even if it is a tooling limitation.

**Other completeness issues**:
- Phase 3 (EXPAND) was not executed: no STRING or BioGRID interaction data was retrieved. The Gaps section acknowledges this (line 215).
- No WikiPathways data was retrieved for DNA damage response or cell cycle checkpoint pathways.
- STK11/LKB1 is mentioned (line 25) but never developed into a mechanism section with supporting data.

---

## 10. Hallucination Risk -- MEDIUM

**Details**: The report makes a strong grounding claim on line 263: "No training knowledge was used to introduce entities, trial IDs, or mechanistic claims not present in tool outputs." However, several elements raise concern:

**Potentially training-derived claims**:

1. **KRAS mutations (30-40% of lung adenocarcinomas)** (line 42): The specific prevalence range is not attributed to any tool output. The Open Targets association score (0.778) is sourced, but the "30-40%" figure appears to come from background knowledge.

2. **TP53 mutations (50-70% of NSCLC, 90%+ of SCLC)** (line 58): The Evidence Assessment table (line 189) correctly flags this as L2 with "single database" justification, but the "90%+ of SCLC" figure is not attributed to any tool call at all.

3. **MTAP is co-deleted with CDKN2A due to chromosomal proximity (9p21)** (line 88): The 9p21 locus detail and the co-deletion mechanism are not attributed to any tool output. The source is `clinicaltrials_search_trials`, which returns trial-level data, not genomic locus information.

4. **BER dependency rationale** (line 42): "KRAS mutations drive chronic oxidative stress and DNA damage, creating dependency on base excision repair" -- this mechanistic narrative is not attributed to any specific tool output. The report acknowledges this in the Gaps section (line 223): "lacks direct retrieval of the oxidative stress -> DNA damage -> BER pathway."

5. **ChEMBL target IDs** (lines 108-120): CHEMBL:3105 (PARP1 target), CHEMBL:5024 (ATR target), CHEMBL:5491 (WEE1 target) appear in the Drug Candidates table without any sourcing to a tool call.

6. **"40-50% of lung adenocarcinomas" co-occurrence of KRAS/TP53** (line 12): No tool call cited for this epidemiological statistic.

**Mitigating factors**:
- The report is transparent about what was and was not retrieved.
- Evidence grading appropriately penalizes single-source claims.
- The Gaps section is thorough and honest about missing data.
- All NCT IDs appear to have come from `clinicaltrials_search_trials` results (not fabricated).

**Risk assessment**: MEDIUM. The core structure (drug-target mappings, trial identifications) appears grounded in tool outputs. However, the mechanistic narratives connecting these data points contain biological details (prevalence figures, pathway logic, chromosomal context) that likely originate from training knowledge rather than tool calls. This is a common pattern where the "connective tissue" of a report draws on background knowledge while the "nodes" (entities, IDs, trial data) come from tools.

---

## Summary Scorecard

| # | Dimension | Score | Key Finding |
|---|-----------|-------|-------------|
| 1 | CURIE Resolution | **FAIL** | 12/16 drugs lack CURIEs; MTAP, CDKN2A, MAT2A, SCLC unresolved; disease CURIE format wrong |
| 2 | Source Attribution | **PASS** | ~55-60 sourced claims; format correct; minor unsourced prevalence figures |
| 3 | LOCATE->RETRIEVE | **PASS** | Two-step pattern evident for 13 resolved entities; 12 drugs never LOCATEd |
| 4 | Disease CURIE in ENRICH | **FAIL** | Obtained incidentally from KRAS associations, not deliberately; SCLC missing; wrong format |
| 5 | Open Targets Pagination | **PASS** | No direct GraphQL used; MCP tools handled pagination |
| 6 | Evidence Grading | **PASS** | 9 claims individually graded; median/range computed; modifiers applied |
| 7 | Gain-of-Function Filter | **N/A** | Not applicable to loss-of-function/synthetic lethality context |
| 8 | Clinical Trial Validation | **FAIL** | 0/26 NCT IDs verified; Phase 5 entirely skipped |
| 9 | Completeness | **FAIL** | No patent coverage; no PubMed literature search; Phase 3 skipped |
| 10 | Hallucination Risk | **MEDIUM** | Prevalence figures and mechanistic narratives likely from training; core data grounded |

**Overall: PARTIAL (5 PASS, 4 FAIL, 1 N/A)**

---

## Recommendations for Improvement

1. **Complete CURIE resolution**: Run `chembl_search_compounds` or `pubchem_search_compounds` for all 16 drugs. Resolve MTAP, CDKN2A, MAT2A, and BRCA1/2 to HGNC CURIEs. Resolve SCLC to a separate disease CURIE.

2. **Run Phase 5 validation**: Call `clinicaltrials_get_trial` for at least the top 10-15 NCT IDs. This is the single highest-impact improvement, converting 26 "Unverified" entries to validated data points.

3. **Add PubMed searches**: Call `pubmed_search_articles` for "synthetic lethality lung cancer" and mechanism-specific queries. This addresses the "literature" component of the competency question.

4. **Acknowledge patent gap explicitly in Summary**: The patent gap is noted in Gaps and Limitations but should be flagged in the Summary since patents are one of three pillars requested in the competency question.

5. **Run Phase 3 (EXPAND)**: Query STRING for KRAS-PARP1, TP53-ATR, TP53-WEE1 interactions. Query WikiPathways for DNA damage response and cell cycle checkpoint pathways. This would strengthen mechanism chain evidence from L2-L3 to L3+.

6. **Fix disease CURIE format**: Change `EFO_0003060` to `EFO:0003060` to match the CURIE convention in the graph-builder skill.

7. **Remove or source prevalence figures**: Either attribute "30-40%", "50-70%", "90%+", "~15%", and "40-50%" to specific tool calls, or explicitly flag them as "estimated from trial populations, not retrieved from genomic databases" with an L1 evidence grade.
